Cidara Therapeutics Inc’s recently made public that its Chief Medical Officer Davarpanah Nicole Negar unloaded Company’s shares for reported $29797.0 on Sep 11 ’25. In the deal valued at $62.86 per share,474 shares were sold. As a result of this transaction, Davarpanah Nicole Negar now holds 31,418 shares worth roughly $3.55 million.
Then, RA CAPITAL MANAGEMENT, L.P. bought 2,272,727 shares, generating $99,999,988 in total proceeds. Upon buying the shares at $44.00, the Director now owns 3,365,523 shares.
Before that, Mineo Chrysa bought 2,270 shares. Cidara Therapeutics Inc shares valued at $49,281 were divested by the Director at a price of $21.71 per share. As a result of the transaction, Mineo Chrysa now holds 2,270 shares, worth roughly $0.26 million.
JP Morgan initiated its Cidara Therapeutics Inc [CDTX] rating to an Overweight in a research note published on October 10, 2025; the price target was $200. Citizens JMP began covering CDTX with “Mkt outperform” recommendation on March 12, 2025.
Price Performance Review of CDTX
On Friday, Cidara Therapeutics Inc [NASDAQ:CDTX] saw its stock jump 2.07% to $113.05. Over the last five days, the stock has gained 10.84%. Cidara Therapeutics Inc shares have risen nearly 955.56% since the year began. Nevertheless, the stocks have risen 320.57% over the past one year.
How much short interest is there in Cidara Therapeutics Inc?
A steep rise in short interest was recorded in Cidara Therapeutics Inc stocks on 2025-09-30, growing by 0.9 million shares to a total of 3.05 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 2.15 million shares. There was a rise of 29.39%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 13, 2024 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $34 price target.
